Brazil Guillain-Barre Syndrome (GBS) Therapeutics Market Report 2023 to 2030

Brazil Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis

$ 3999

Brazil Guillain-Barre Syndrome (GBS) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Guillain Barre Syndrome is a rare autoimmune disorder in which persons immune system attacks nervous system. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.

ID: IN10BRRD030 CATEGORY: Rare Diseases GEOGRAPHY: Brazil AUTHOR: Gaurav Bhongale

Buy Now

Brazil Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis Summary

Brazil Guillain-Barre Syndrome (GBS) Therapeutics Market is valued at around $0.015 Mn in 2022 and is projected to reach $0.03 Mn by 2030, exhibiting a CAGR of 6.2% during the forecast period 2023-2030.

In Guillain-Barre syndrome (GBS), a portion of the peripheral nerve system is attacked by the body's immune system. Leg tingling or weakness in varied degrees are among the disorder's initial symptoms. When these symptoms are severe, the person is almost completely paralysed and specific muscles can no longer be utilised at all. Complement C5, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Complement C1q Subcomponent, and others are the main targets of the GBS pipeline pharmaceuticals industry. Monoclonal antibodies, small molecules, peptides, cell therapies, polymers, proteins, recombinant enzymes, recombinant proteins, and subunit vaccines are the main chemical categories in the GBS pipeline pharmaceuticals market. Monoclonal antibodies and intravenous immunoglobulins are projected to dominate the global market in coming years. Increasing collaboration between research organizations, academic institutions and pharmaceutical companies for research and development also acts as a market growth driver. The rise in new product approvals due to accelerated drug approval by regulatory bodies acts as a market growth driver. Lack of awareness of Guillain-Barre Syndrome and the absence of any definitive treatment are expected to act as major market growth restraints.

Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, and Chugai Pharmaceutical Co Ltd are the key market players operating in the global Gillian barre syndrome drugs market.

Market Dynamics

Market Drivers

The rise in new product approvals due to accelerated drug approval by regulatory bodies acts as a market growth driver.

The rise in the geriatric population leading to the prevalence of immune disorders like multiple sclerosis, acute motor axonal neuropathy and rise in infections due to Epstein-Barr virus, Zika virus, and others also acts as a market growth driver.

Increasing collaboration between research organizations, academic institutions and pharmaceutical companies for research and development also acts as a market growth driver.

Market Development

Based on controlled trials done by Network Meta-Analysis (NMA), IgG therapy has been approved for the treatment of Guillain-Barré syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and dermatomyositis.

Nomacopan by Akari Therapeutics is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), uveitis, atopic keratoconjunctivitis (AKC), Guillain-Barre syndrome and many others.

Market Restraints

Lack of awareness of Guillain-Barre Syndrome and the absence of any definitive treatment are expected to act as major market growth restraints.

Key players

Pfizer Sanofi BioMarin Pharmaceutical Inc. Catalyst Biosciences uniQure Ionis Pharmaceuticals Alnylam Pharmaceuticals Intercept Pharmaceuticals Novartis Roche

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Brazil Guillain-Barre Syndrome (GBS) Therapeutics market

By Type

Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
Miller-Fisher Syndrome (MFS)
Acute Motor Axonal Neuropathy (AMAN)

By Therapy

Intravenous Immunoglobulin
Plasma Exchange
Small molecule
Peptide
Others

By Diagnosis

Lumbar Puncture
Electromyography
Nerve Conduction Studies
Others

By treatment

Plasmapheresis
Medication
Physical Therapy
Hydrotherapy
Others

By Route of Administration

Oral
Parenteral

By end users

Hospitals
Diagnostic centres
Clinics
Others

By Distribution Channels:

Hospital pharmacies
Retail pharmacies
Online pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.